HK1176363A1 - Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies 1- - Google Patents

Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies 1-

Info

Publication number
HK1176363A1
HK1176363A1 HK13103661.7A HK13103661A HK1176363A1 HK 1176363 A1 HK1176363 A1 HK 1176363A1 HK 13103661 A HK13103661 A HK 13103661A HK 1176363 A1 HK1176363 A1 HK 1176363A1
Authority
HK
Hong Kong
Prior art keywords
receptor peptides
inhibiting beta
peptides inhibiting
mutant double
cyclized
Prior art date
Application number
HK13103661.7A
Other languages
English (en)
Chinese (zh)
Inventor
Roland Jahns
Valrie Jahns
Martin Lohse
Viacheslav Nikolaev
Original Assignee
Julius Maximilians Universitt Wrzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitt Wrzburg filed Critical Julius Maximilians Universitt Wrzburg
Publication of HK1176363A1 publication Critical patent/HK1176363A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
HK13103661.7A 2007-08-24 2013-03-25 Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies 1- HK1176363A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07016637 2007-08-24

Publications (1)

Publication Number Publication Date
HK1176363A1 true HK1176363A1 (en) 2013-07-26

Family

ID=40130559

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13103661.7A HK1176363A1 (en) 2007-08-24 2013-03-25 Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies 1-

Country Status (14)

Country Link
US (1) US9062095B2 (fr)
EP (3) EP2197900B9 (fr)
JP (3) JP5248610B2 (fr)
CN (2) CN101835793B (fr)
AU (1) AU2008291296B2 (fr)
CA (1) CA2697108C (fr)
DK (1) DK2197900T3 (fr)
ES (1) ES2391358T3 (fr)
HK (1) HK1176363A1 (fr)
HR (1) HRP20120827T1 (fr)
PL (1) PL2197900T3 (fr)
PT (1) PT2197900E (fr)
SI (1) SI2197900T1 (fr)
WO (1) WO2009027063A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697108C (fr) * 2007-08-24 2018-05-22 Julius-Maximilians-Universitaet Wuerzburg Recepteurs peptidiques cyclises double mutants inhibiteurs d'anticorps anti-recepteurs .beta.1-adrenergiques
EP2391637A1 (fr) * 2009-01-27 2011-12-07 Julius-Maximilians-Universität Würzburg Nouveaux homologues peptidiques pour l'inhibition d'anticorps dirigés contre l'adrénorécepteur bêta1
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor
EP2402016A1 (fr) * 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamères qui inhibent l'interaction entre un anticorps et du 1ère et 2ème loop extracellulaire de récepteur bêta 1-adrénergique humain
EP2718324A1 (fr) 2011-06-10 2014-04-16 Corimmun GmbH Composés de liaison au 1-adrénorécepteur ( 1-ar) humain et leur utilisation dans la mesure d'auto-anticorps anti- 1-ar
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­ｔｒｎａ 신테타제
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
JPWO2015022953A1 (ja) * 2013-08-14 2017-03-02 国立大学法人 長崎大学 血液脳関門障害改善剤
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
CN108218963B (zh) * 2018-01-19 2020-10-13 首都医科大学 一种环肽及其制备方法和用途
WO2020186176A1 (fr) * 2019-03-14 2020-09-17 Genentech, Inc. Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé de séquestration d'anticorps indésirables chez un patient
JP2023542389A (ja) * 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
CN112266330B (zh) * 2020-10-15 2023-02-24 长沙博源医疗科技有限公司 一种甲氧基肾上腺素衍生物、免疫原、抗甲氧基肾上腺素特异性抗体及其制备方法与应用
EP4392430A1 (fr) * 2021-08-27 2024-07-03 Yale University Agents de dégradation moléculaires de protéines extracellulaires
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (fr) 1982-06-23 1987-07-07 Dean Engelhardt Nucleotides modifies, methodes de preparation et d'utilisation et composes les contenant
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
AU7521800A (en) * 1999-09-21 2001-04-24 Affina Immuntechnik Gmbh Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm)
JP2003513942A (ja) * 1999-11-05 2003-04-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ遺伝子送達による心血管疾患を処理するための技術および組成物
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP4541490B2 (ja) 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
AU2001259195A1 (en) * 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
CN1988914A (zh) * 2001-08-23 2007-06-27 西兰制药公司 胞间通讯易化化合物的新医学用途
US7041790B2 (en) * 2002-03-26 2006-05-09 Dyax Corp. Fibrinogen binding moieties
WO2004069863A2 (fr) * 2003-02-04 2004-08-19 New York University Peptides contraints de la boucle v3 du vih-1 utilises comme immunogenes et antagonistes des recepteurs
EP1536020A1 (fr) 2003-11-26 2005-06-01 Bayerische Julius-Maximilians-Universität Würzburg Dispositifs et procédés pour la determination optique de cAMP in vitro et in vivo
JP5350779B2 (ja) * 2005-03-31 2013-11-27 ユリウス−マクシミリアンズ−ユニバーシタット ブルツブルグ 抗β１アドレナリン受容体抗体を阻害する手段
CA2697108C (fr) * 2007-08-24 2018-05-22 Julius-Maximilians-Universitaet Wuerzburg Recepteurs peptidiques cyclises double mutants inhibiteurs d'anticorps anti-recepteurs .beta.1-adrenergiques

Also Published As

Publication number Publication date
EP2497777A3 (fr) 2012-10-10
EP2559698A3 (fr) 2013-03-06
JP5248610B2 (ja) 2013-07-31
SI2197900T1 (sl) 2012-11-30
JP2010536356A (ja) 2010-12-02
CA2697108A1 (fr) 2009-03-05
EP2497777A2 (fr) 2012-09-12
DK2197900T3 (da) 2012-10-22
AU2008291296A1 (en) 2009-03-05
US9062095B2 (en) 2015-06-23
AU2008291296B2 (en) 2014-02-06
EP2197900A2 (fr) 2010-06-23
EP2559698B1 (fr) 2014-11-12
WO2009027063A2 (fr) 2009-03-05
HRP20120827T1 (hr) 2012-11-30
JP2013176369A (ja) 2013-09-09
PL2197900T3 (pl) 2012-12-31
CN101835793B (zh) 2014-04-23
PT2197900E (pt) 2012-10-24
ES2391358T3 (es) 2012-11-23
EP2197900B1 (fr) 2012-08-01
EP2559698A2 (fr) 2013-02-20
CN101835793A (zh) 2010-09-15
EP2197900B9 (fr) 2013-01-09
US20100209445A1 (en) 2010-08-19
CN103992406A (zh) 2014-08-20
CA2697108C (fr) 2018-05-22
WO2009027063A3 (fr) 2009-07-23
JP2013138679A (ja) 2013-07-18

Similar Documents

Publication Publication Date Title
HK1176363A1 (en) Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies 1-
HK1244694A1 (zh) 新穎的胰高血糖素受體拮抗劑
HRP20151108T1 (en) Nogo receptor antagonists
EP2184278A4 (fr) Antagoniste de récepteur p2x4
EP2151236A4 (fr) Agoniste de récepteur couplé aux protéines g
IL204536A0 (en) Anti - il -6 receptor antibody
EP2058304A4 (fr) Antagoniste du récepteur p2x4
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
EP2099454A4 (fr) Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
HK1136302A1 (en) Progesterone receptor antagonists
IL212551A0 (en) Cxcr4 receptor compounds
IL187424A0 (en) C5a RECEPTOR ANTAGONISTS
IL184278A0 (en) C5a RECEPTOR ANTAGONISTS
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
EP2191830A4 (fr) Préparation solide comprenant un antagoniste du récepteur npyy5
HK1163063A1 (en) Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity 5-ht2b -3-
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
EP2153736A4 (fr) Antagoniste inédit du récepteur des leucotriènes
EP2478001A4 (fr) Composés peptidiques bénéfiques de récepteur aux opiacés mu
IL202454A0 (en) Urotensin ii receptor antagonists
EP2229400A4 (fr) Sels avantageux de peptides des récepteurs opioïdes mu
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
ZA200903499B (en) Indoles which act as via receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190824